$JNJ Key levels, Analysis & Targets$JNJ Key levels, Analysis & Targets
Forecasting stock prices using Fibonacci theory to analyze price levels for "Stop Loss" and "Take Profit".
DJNJ3 trade ideas
PharmaPharmaPharmaPharmaklnasdklasndklandklsndklanda
sadklasldnaskldnaskl
akldnaskldnakldnaslkand
adklnaslkdn
JNJ 1D EW countJNJ still in the correction mode, today's bounce is not impulse and looks to be ABC for wave 2 in the final leg of the downside. Expecting to bottom around 140 area. Let's see how this plays out.
Long JNJ @ 167.62Weekly fractal of 167.62 has been hit, after a sleeping alligator on both daily and weekly.
Price is now on the bullish side of the alligator's mouth for both timeframes.
Stop loss is the daily redline which today is 160.42 and in 5 days it will be 162.58.
There are no more fractals on the daily chart. We will see any newly created bullish signal for possible add ons.
J&J Breakout over 174A daily close above 174 is super bullish. I am sort of conflicted though on the over all trade. The chart has been in a trading range since Feb 2021 and it is finally breaking out but and this is a BIG BUT........ It is on LOW volume and we all know how that normally turns out so my thesis is short term bullish on this specific trade.
JNJ ideaIf we keep seeing rotation into value, JNJ is a good pick imo
Entry: 173.50
Target: 175.30 / 179.65
***Disclaimer: This is just a trading idea, not a financial advise***
Johnson & Johnson | Fundamental Analysis | LONG SETUP โก๏ธFor much of the previous decade, the stock of diversified healthcare behemoth Johnson & Johnson has consistently delivered market returns (if you count dividends as part of total return on equity). Investors flocked to this company because of its solid balance sheet, its status as a dividend aristocrat, and its unique ability to consistently bring new blockbuster pharmaceutical products to market in a timely manner.
Since the beginning of this decade, however, J&J stock has largely underperformed the broader markets. The stock has lost its luster recently because of the baby powder litigation, the lack of enthusiasm among investors for the $30 billion acquisition of Actelion, the maker of pulmonary arterial hypertension drugs, its high valuation, and the relatively low sales of its COVID-19 vaccine.
Will J&J stock be able to return to its previous market successes or should investors move to a more favorable environment? Here's a look at both sides of the question.
1. J&J may be one of the top stocks in healthcare today, but this $444 billion titan is about to undergo some major changes that could lead to a decline in its performance.
According to a Nov. 12 announcement, the company plans to split into two businesses over the next 24 months. One of the new businesses will focus on consumer health products and the other on the development and commercialization of pharmaceuticals and medical devices. The transition will be one of the largest in the company's 135-year history, and it will entail reshuffles in all areas, including senior management.
This means that serious risks loom on the horizon that shareholders have not yet had to deal with. Splitting the business in two may turn out for the best, but it's important to remember that things haven't been going in the right direction for some time. Over the past five years, quarterly revenue has grown by only 28.9 percent, while quarterly profit margins have fallen by 25.4 percent. Similarly, quarterly net income is down 3.85% and quarterly free cash flow (FCF) is down more than 19% over the same period. There is no guarantee that the separation will solve these problems.
In addition to the uncertainties associated with the separation, the company also faces new hurdles regarding revenue from the coronavirus vaccine, which is expected to bring in $2.5 billion in 2021. On Dec. 16, the Centers for Disease Control and Prevention issued a recommendation that the company's vaccine should not be used if vaccines from competitors such as Pfizer are available. The recommendation comes amid ongoing concerns about the J&J vaccine's poor efficacy and its ability to cause rare and life-threatening complications in some people.
Therefore, this is a particularly risky time to invest in J&J stock. Time will tell if the company can gracefully survive its breakup.
2. Wall Street has not been particularly receptive to J&J's proposed separation and for good reason. After all, the company's health care division contains several iconic brands, such as Benadryl and Tylenol, which are proven cash cows. Wall Street's fears about this separation, however, may have been exaggerated. As evidence, Pfizer recently went through a slimming process, separating its legacy products business without any adverse consequences.
And J&J, for its part, seems more than capable of pulling off the same maneuver without any major hitches. This is evidenced by a wide range of fast-growing pharmaceutical products, such as the multiple myeloma drug Darzalex, the immune-mediated inflammatory disease drug Stelara, and the plaque psoriasis drug Tremfya.
It was these three key products that drove the company's pharmaceutical segment in the third quarter of 2021, up 13.8% from a year ago, excluding acquisitions and sales. Moreover, J&J is one of the best in the business at launching new pharmaceutical products for areas with large unmet medical needs.
In fact, this separation should allow the company's pharmaceutical division to shine from a top-line perspective. And that's a big plus for growth-oriented investors.
Income investors may be concerned about the potential impact on the company's much-desired dividend. Fortunately, J&J management has already said that future dividend payments should remain about the same as the current quarterly distribution after the split.
Overall, J&J stock seems poised to turn into a top play for growth and earnings after the upcoming split.
JNJ poised for a breakout of resistanceJNJ in an attempt to breakout resistance @ 170-172 with a good setup pattern. Please see the details on the chart. Take notice that JNJ is a defensive stock, just in case.
Thx.
JNJ Formed a nice Double Bottom patternHi everyone,
$JNJ formed a nice Double Bottom pattern on Daily timeframe . The price hit twice the strong support formed at around 155 price level.
It recently broke the resistance level at 167 and now it is ready to test it again as a support level.
If tested successfully it offers a really nice buy setup.
If you like the idea, do not forget to support with a like and follow.
* ๐ง๐ต๐ฒ ๐ถ๐ป๐ณ๐ผ๐ฟ๐บ๐ฎ๐๐ถ๐ผ๐ป ๐ฎ๐ป๐ฑ ๐ฎ๐ป๐ฎ๐น๐๐๐ถ๐ ๐๐ต๐ฎ๐ฟ๐ฒ๐ฑ ๐ถ๐ป ๐๐ต๐ถ๐ ๐ฝ๐ผ๐๐ ๐ถ๐ ๐ป๐ผ๐ ๐ณ๐ถ๐ป๐ฎ๐ป๐ฐ๐ถ๐ฎ๐น ๐ฎ๐ฑ๐๐ถ๐ฐ๐ฒ ๐ฎ๐ป๐ฑ ๐ถ๐ ๐ณ๐ผ๐ฟ ๐ฒ๐ฑ๐๐ฐ๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐ฝ๐๐ฟ๐ฝ๐ผ๐๐ฒ ๐ผ๐ป๐น๐! ๐๐น๐๐ฎ๐๐ ๐ฐ๐ผ๐ป๐ฑ๐๐ฐ๐ ๐๐ผ๐๐ฟ ๐ผ๐๐ป ๐ฎ๐ป๐ฎ๐น๐๐๐ถ๐ ๐ฎ๐ป๐ฑ ๐ฟ๐ฒ๐๐ฒ๐ฎ๐ฟ๐ฐ๐ต.
$JNJ...Nice relative strength today on this name which we pointed out on the live stream in our group. Market fading some gaps, but whole market not crashing as healthcare and others with nice moves so far! Go with what's strong! $PFE still going from yesterday too!
johnson & johnson(jnj) is collecting its potential for new ATHAfter correction, NYSE:JNJ started its bulling trend to break its ATH.
Note: Market has two sides and we should not trade according to prediction and assumption, while you should notice the time of the market.
$JNJ breaks todays resistance. $JNJ possible bullish continuation after breaking out from todays resistance.
buy calls above $171.50
buy puts below 167.76
JNJ (Johnson & Johnson) is BullishPrice closed above EMA 10, EMA 20, and Horizontal Support Resistance Level.
Mega Candle in Johnson & JohnsonJohnson & Johnson is often a dull stock, but it had some exciting price action yesterday.
The health care giant dropped 1 percent in the initial seconds of trading, undercutting Fridayโs low. Buyers immediately came out of the woodwork, driving the stock to its highest close in over three months. The result was a large bullish outside candle.
Next, the surge planted JNJ back above its 200-day simple moving average (SMA) for the first time in almost as long.
Third, the recent bounces near $158 created something of a W-shaped double bottom.
Fourth, safe-havens like health care have gained relative strength in the last week as investors brace for a hawkish Federal Reserve.
JNJ has also enjoyed some interesting news lately. Quarterly results on October 19 were better than expected. It followed on November 12 with a plan to split into two companies. Thatโs potentially a big deal because spinoffs can allow multiple expansion as investors assign different valuations to various business lines.
TradeStation is a pioneer in the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more.
Important Information
TradingView is not affiliated with TradeStation Securities Inc. or its affiliates. TradeStation Securities, Inc., TradeStation Crypto, Inc., and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., all operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Please click here for further important information explaining what this means.
This content is for informational and educational purposes only. This is not a recommendation regarding any investment or investment strategy. Any opinions expressed herein are those of the author and do not represent the views or opinions of TradeStation or any of its affiliates.
Investing involves risks. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options, futures, or digital assets); therefore, you should not invest or risk money that you cannot afford to lose. Before trading any asset class, first read the relevant risk disclosure statements on the Important Documents page, found here: www.tradestation.com .
$JNJ bullish continuation. $JNJ setup looks good right now. it could possibly continue to go up tomorrow. just FYI this stock moves about $2-2.50 on average. so its moves kinda slow. next resistance is $170.50 buy above 169.24 sell at 166.70
Johnson & johnson BUY opportunity on DEMAND ZONENice opportunity to go long on JNJ within the area between 161 and 165.
The best is to wait until the price enter the zone highlighted.
The level should hold the price between this zone, so keep an eye on it and secure your profits.
Happy trading.
Signal buy $JNJTSI Shadow triggered a bullish crossover and candles have closed above the Filter Line. I will buy shares at the open today.
I will scale out 50% of my position when it hits 3R (11.63%) and let the rest run until price close below the 100-200 cloud/ribbon
I will not close the trade if price close below the 100-200 EMA cloud before price reaches the 3R, i will let it open until it hits the stoploss
Discounted Cash Flow valuation between $ 207 to $ 227
JNJ Potential for a move upI am a data science enthusiast and decided to share some of my models results here. My current model scans over 300 stocks and 300 etfs. It tries to predict probable moves over the next 10 trading days. JNJ has been one that has been highlighted. Think the model is on to something considering that it has had quite a move down the last few months. The model has predicted 6 for JNJ which means it is expecting a reasonable move up over the next 10 days.
I use python for all my scripting of the machine learning. If you know about sklearn it can generate a confusion matrix like below for JNJ. I have included the confusion matrix on the chart where columns are what my model predicted and the rows are what the values actually were. The values 0 to 1 are indicative of a negative return over the next 10 trading days and 2 to 7 positive moves. 0 means a are large expected down move and 7 a large expected upward move for the stock.
Also have a look at my Patreon page where I publish more ideas: www.patreon.com
A bit of positive divergence.Perhaps JNJ can lift-off after a long consolidation. We have a bit of positive divergence on our side (price down/RSI up), along with negative real interest rates and positive seasonality.
JNJNYSE:JNJ formed a head and shoulder on a daily time frame it will reach the target when it breaks the neck down
JNJ - STOCKS - 29. OCT. 2021Welcome to our Weekly V2-Trade Setup ( JNJ ) !
-
4 HOUR
Bearish turnover towards main sr!
DAILY
Expecting another push to the upside..
WEEKLY
Great long entries and pa
-
STOCK SETUP
BUY JNJ
ENTRY LEVEL @ 161.48
SL @ 159.16
TP @ Open
Max Risk: 0.5% - 1%!
(Remember to add a few pips to all levels - different Brokers!)
Leave us a comment or like to keep our content for free and alive.
Have a great week everyone!
ALAN
JNJ...did not bottom yet... C wave just started... JNJ.... has not bottomed yet... C wave has just started... potential bottom at 144... and then potential for it to start 5th wave rally... we will see..not confident on this.
